In this informative video, Dr. Frères (CHU de Liège) highlights some exciting presentations from an oral abstract session on kidney and bladder cancer.
One of the primary findings he discussed was the results of a phase 3, randomized study called CONTACT-03. This study compared atezolizumab plus cabozantinib with cabozantinib alone for patients with metastatic renal cell carcinoma who had previously received immune checkpoint inhibitor treatment.
Another study he mentioned was the phase 3 CheckMate 914 (part A) trial, which investigated the effectiveness of adjuvant nivolumab plus ipilimumab versus placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy.
In the phase 2 Norse study, erdafitinib was tested alone and in combination with cetrelimab for patients with metastatic urothelial carcinoma and fibroblast growth factor receptor alterations. The EV-103 dose escalation study looked at the long-term outcomes of enfortumab vedotin plus pembrolizumab in first-line cisplatin-ineligible patients.
Finally, Dr. Frères reported on the VESPER trial, with 5-year overall results of dose-dense MVAC to gemcitabine and cisplatin as perioperative chemotherapy for muscle-invasive bladder cancer. We hope you find this information helpful!
With the educational support of:
